This presentation release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company's priorities and achieve key clinical milestones; the company's plans to present data from its Friedreich's ataxia program, next-generation Duchenne muscular dystrophy program, novel capsid program, and process developme ...

` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-0943402 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Biosciences Inc. (Exact name of Registrant as specified in its Charter) Delaware 90-0943402 (State or other jurisdiction ...

© 2022 Solid Biosciences 1 Strategic Update: Acquisition of AavantiBio and $75M PIPE September 30, 2022 Forward-Looking Statements and Industry and Market Data This presentation and various remarks we make during this presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding: future expectations, plans and prospects for Solid Biosciences Inc. (the "Company" or "Solid"), AavantiBio, Inc. ("AavantiBio") and the ...

Solid Biosciences Inc. (NASDAQ:SLDB) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communications and IR Ilan Ganot - Co-Founder, President and CEO Dr. Joel Schneider - COO Dr. Carl Morris - Chief Scientific Officer Dr. Roxana Donisa Dreghici - SVP and Head, Clinical Development Conference Call Participants Gena Wang - Barclays Joseph Schwartz - SVB Securities Allison Bratzel - Piper Sandler Anupam Rama - JP Morgan Maury Raycroft - Jefferies Operator Ladi ...

© 2021 Solid Biosciences1 Solid Biosciences Corporate OverviewOctober 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's IGNITE DMD clinical trial, ability of the Company to continue dosing patients in the IGNITE DMD trial, the implication of interim clinical data, the safety or potential treatment benefits of SGT-001 in patients with Duchenne, the Com ...

Solid Biosciences Inc. (NASDAQ:SLDB) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Tim Palmer – Manager-Corporate Communications Ilan Ganot – Co-Founder, President and Chief Executive Officer Cathryn Clary – Acting Chief Medical Officer Carl Morris – Chief Scientific Officer Joel Schneider – Chief Operating Officer Conference Call Participants Joseph Schwartz – SVB Leerink Gena Wang – Barclays Salveen Richter – Goldman Sachs Gbola Amusa – Chardan Maneka Mirchandaney – Evercor ...

SGT-001 Interim Clinical Results From IGNITE-DMD Ilan Ganot, Co-founder, President, and CEO March 15, 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's IGNITE DMD clinical trial, ability of the Company to continue dosing patients in the IGNITE DMD trial, the implication of interim clinical data, the safety or potential treatment benefits of SGT-001 in ...

Solid Biosciences Inc (NASDAQ:SLDB) Q3 2020 Earnings Conference Call November 5, 2020 8:30 PM ET Company Participants Jennifer Ziolkowski – Chief Financial Officer Ilan Ganot – Co-Founder, President and Chief Executive Officer Joel Schneider – Chief Technology Officer Cathryn Clary – Acting Chief Medical Officer Conference Call Participants Mark Connolly – Credit Suisse Joseph Schwartz – SVB Leerink Operator Ladies and gentlemen, thank you for standing by and welcome to the Solid Biosciences Update Call. At ...

© 2019 Solid Biosciences 1 Solid Biosciences Corporate Overview January 2019 Forward-Looking Statements This presentaDon includes "forward-looking statements" within the meaning of the Private SecuriDes LiDgaDon Reform Act of 1995, which involve a number of risks and uncertainDes. These forward-looking statements include all maOers that are not historical facts and, without limiDng the foregoing, can be idenDfied by the use of forward-looking terminology, including the terms "believe," "esDmate," "project," ...